Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 262

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 262
---
4,      
 the loan balance, accrued interest and accrued risk premium was $169.                         |

| The risk premium was accounted as additional interest to                                    
 be paid upon maturity date, and the Company amortized such interest expense during the term 
 of the loan using the effective interest method.                                            |

| c. | Between October                                                                               
 2024 and November 2024, the Company entered into the October 2024 bridge loan agreements,     
 pursuant to which the Company obtained a bridge loan (the “Bridge Loans”) from                
 the lenders thereto including certain related parties (the “Bridge Loan Lenders”).            
 The Bridge Loans will be repaid at the earlier of consummation of an IPO or on March 31,      
 2025 (the “Bridge Loans Maturity Date”) and bear interest at 8% per annum until               
 maturity commencing as of September 1, 2024. In October 2024, the Company amended the Bridge  
 Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and until      
 June 30, 2025, subject to the Registration Statement effectiveness not later than March 31,   
 2025 and the fulfillment of additional cumulative conditions. In addition, at the Bridge      
 Loans Maturity Date, the Company will pay the Bridge Loan Lenders, on a pro rata basis to     
 each Bridge Loan Lender participation to the loan amount, an aggregate risk premium equal     
 to 30% of the loan amount. Furthermore, upon the occurrence of an IPO for a total offering    
 of not less than $6,000, the Bridge Loan Lenders, will be granted warrants to purchase such   
 number of Ordinary Shares equal to two times the loan amount based on a price per share equal 
 to 75% of the lowest price per share of the Ordinary Shares, during the first five trading    
 days from the consummation of an IPO. As of December 31, 2024, the Company raised $250 under  
 such Bridge Loans. As of December 31, 2024, the loan balance, accrued interest and accrued    
 risk premium was $281. On March 31, 2025, the Company and the lenders signed an amendment     
 to the loan agreement to extend the maturity date of the Bridge Loans until the earlier of    
 August 31, 2025 or the consummation of an IPO.                                                |

| The risk premium was accounted as additional interest to be paid upon maturity date, and the Company